C-FEJZAAV gene therapy, CMV gene therapy, cellular aging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop gene therapy approaches intended to help patient cells behave more youthfully, ward off age-related degeneration, lengthen healthy human lifespan, and treat cellular aging.
Adeno-associated virus (AAV) gene therapy platform for delivering genetic payloads related to aging-associated diseases.
Company site describes BioViva as developing AAV gene therapy for healthy lifespan extension and cellular aging.
Use high-capacity cytomegalovirus vectors as a gene delivery system for protective factors associated with healthy life extension.
Intranasal and injectable cytomegalovirus vector delivery of longevity-associated genes, including TERT and FST in animal models.
2022 PNAS publication reported CMV vectors used intranasally and by injection to deliver TERT or FST in mice.
MCMV-TERT extended median mouse lifespan by 41.4% and MCMV-FST by 32.5%; reported improvements included glucose tolerance, physical performance, prevention of body mass loss and alopecia, reduced telomere shortening with TERT, and halted mitochondrial structural deterioration without reported carcinogenicity or unwanted side effects.
Provide an open access database for gene therapy.
Database platform for gene therapy information.
Company description states BioViva operates CodeKeeper as an open access database for gene therapy.
Deliver follistatin to mitigate aging-related decline and extend healthy lifespan.
Mouse cytomegalovirus vector carrying exogenous FST, administered intranasally or by injection.
Preclinical mouse study published in PNAS in 2022.
Reported 32.5% median lifespan extension, improved glucose tolerance and physical performance, prevention of body mass loss and alopecia, halted mitochondrial structural deterioration, and no reported carcinogenicity or unwanted side effects.
Deliver telomerase reverse transcriptase to mitigate aging-related decline and extend healthy lifespan.
Mouse cytomegalovirus vector carrying exogenous TERT, administered intranasally or by injection.
Preclinical mouse study published in PNAS in 2022.
Reported 41.4% median lifespan extension, improved glucose tolerance and physical performance, prevention of body mass loss and alopecia, amelioration of telomere shortening, and no reported carcinogenicity or unwanted side effects.